Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
PaperCitations, authors & open-access status
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 669 citations, 2018 year and closed oa status.
669
Citations
2018
Year
closed
OA Status